Tag: NO0010852213

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsNO0010852213

InventHelp Inventor Develops New Dust Management System (TLS-837)

European savings and retirement services group Athora to acquire Pension Insurance Corporation Group

FortisBC to issue call for power to help meet energy demand in the Southern Interior

Tag: NO0010852213

EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us